Volume 23, Number 2—February 2017
CME ACTIVITY - Research
Multidrug-Resistant Candida haemulonii and C. auris, Tel Aviv, Israel
This activity has been planned and implemented through the joint providership of Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.
Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at http://www.medscape.org/journal/eid; and (4) view/print certificate.
Release date: January 13, 2017; Expiration date: January 13, 2018
Upon completion of this activity, participants will be able to:
1. Assess the phylogenetic analysis of Candida auris and C. haemulonii in the current study
2. Analyze patient characteristics among infections with C. auris and C. haemulonii
3. Distinguish the pattern of antifungal resistance in infections with C. auris and C. haemulonii
4. Evaluate the pathologic potential of C. auris and C. haemulonii
Karen L. Foster, MA, Technical Writer/Editor, Emerging Infectious Diseases. Disclosure: Karen L. Foster has disclosed no relevant financial relationships.
Charles P. Vega, MD, Clinical Professor of Family Medicine, University of California, Irvine. Disclosure: Charles P. Vega, MD, has disclosed the following financial relationships: served as an advisor or consultant for Allergan, Inc.; McNeil Consumer Healthcare; served as a speaker or a member of a speakers bureau for Shire Pharmaceuticals.
Disclosures: Ronen Ben-Ami, MD, has disclosed the following relevant financial relationships: served as an advisor or consultant for Pfizer, Inc.; Merck & Co. Inc.; Neopharm; Teva Pharmaceuticals. Yasmin Maor, MD, has disclosed the following relevant financial relationships: served as an advisor or consultant for Novo Nordisk; served as a speaker or member of a speakers bureau for Pfizer; MSD. Judith Berman, PhD; Ana Novikov, MSc; Edna Bash, MSc; Yael Shachor-Meyouhas, MD; Shiri Zakin, PhD; Jalal Tarabia, PhD; Vered Schechner, MD, MSc; Amos Adler, MD; and Talya Finn, MBBS, have disclosed no relevant financial relationships.>
- Page created: January 12, 2017
- Page last updated: January 12, 2017
- Page last reviewed: January 12, 2017
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)